Pneumatic displacement and intra-vitreal bevacizumab in management of sub-retinal and sub-retinal pigment epithelial hemorrhage at macula in polypoidal choroidal vasculopathy (PCV): rationale and outcome.
We report three cases of submacular haemorrhage due to polypoidal choroidal vasculopathy (PCV) treated with intravitreal bevacizumab and pneumatic displacement with perfluoropropane (C3F8) gas. The patients were between 45 to 55 years and presented with reduction of vision (20/400 to 20/80) within two weeks of onset of symptoms. The submacular (sub-retinal plus sub-retinal pigment epithelium [RPE]) hemorrhages was confirmed as PCV on indocyanine green angiography and optical coherence tomography in all of them. They were treated with intravitreal bevacizumab (1.25 mg/0.05 ml) and 0.3 ml of 100% C3F8 gas in the affected eye followed by prone positioning for two weeks. The vision and macular anatomy started improving within a week and continued up to three months. These cases demonstrate that pneumatic displacement combined with intravitreal anti-VEGF injection could be a promising option in patients with PCV and sub-macular blood, even when the blood is beneath the RPE.
Retina and Vitreous Service, L. V. Prasad Eye Institute , Bhubaneswar, Orissa , India.
Sameera
S
Nayak
Tapas Ranjan
TR
Padhi
Soumyava
S
Basu
Taraprasad
T
Das
D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage*; D000068258:Bevacizumab; D015862:Choroid Diseases / Q000150:complications*; D003131:Combined Modality Therapy; D005260:Female; D005466:Fluorocarbons / Q000627:therapeutic use*; D006801:Humans; D058449:Intravitreal Injections; D008297:Male; D008875:Middle Aged; D016491:Peripheral Vascular Diseases / Q000150:complications*; D011312:Pressure; D012166:Retinal Hemorrhage / Q000628:therapy*; D055213:Retinal Pigment Epithelium; D016896:Treatment Outcome
D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D005466:Fluorocarbons; D000068258:Bevacizumab; C042852:perflutren
Bevacizumab; polypoidal choroidal vasculopathy; sub-retinal hemorrhage; sub-retinal pigment epithelial hemorrhage